Sebastian Kobold, MD, PhD, Ludwig-Maximilians-Universität München, Munich, Germany, describes a novel CAR-T cell platform designed to enable modular targeting of solid tumors. The P329G-targeting CAR-T cells are combined with antigen-binding human IgG1 antibodies containing the P329G LALA mutations in their Fc part to target EGFR, mesothelin or HER2. This interview took place at the Immunotherapy of Cancer (ITOC) Conference 2022 in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.